CG Oncology, Inc.
Develops bladder-sparing oncolytic immunotherapies for urologic cancers.
CGON | US
Overview
Corporate Details
- ISIN(s):
- US1569441009
- LEI:
- Country:
- United States of America
- Address:
- 400 SPECTRUM CENTER DRIVE, 92618 IRVINE
- Website:
- https://www.cgoncology.com/
- Sector:
- Manufacturing
Description
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing therapeutics for patients with urologic cancers, particularly non-muscle invasive bladder cancer (NMIBC). The company's lead product candidate is cretostimogene grenadenorepvec, an investigational, intravesically delivered oncolytic immunotherapy. This therapy is designed with a dual mechanism of action to selectively replicate within and destroy cancer cells while stimulating a systemic anti-tumor immune response. The primary goal is to provide an effective treatment that preserves the bladder and improves the quality of life for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CG Oncology, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CG Oncology, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CG Oncology, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
